The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Abstract
Purpose: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1–derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III trial. Patients and Methods: Patients with injectable melanoma that was not surgically resectable were randomly assigned at a two-to-one ratio to intralesional T-VEC or subcutaneous GM-CSF. The primary end point was durable response rate (DRR; objective response lasting continuously ≥ 6 months) per independent assessment. Key secondary end points included overall survival (OS) and overall response rate. Results: Among 436 patients randomly assigned, DRR was significantly higher with T-VEC (16.3%; 95% CI, 12.1% to 20.5%) than GM-CSF (2.1%; 95% CI, 0% to 4.5%]; odds ratio, 8.9; P < .001). Overall response rate was also higher in the T-VEC arm (26.4%; 95% CI, 21.4% to 31.5% v 5.7%; 95% CI, 1.9% to 9.5%). Median OS was 23.3 months (95% CI, 19.5 to 29.6 months) with T-VEC and 18.9 months (95% CI, 16.0 to 23.7 months) with GM-CSF (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P = .051). T-VEC efficacy was most pronounced in patients with stage IIIB, IIIC, or IVM1a disease and in patients with treatment-naive disease. The most common adverse events (AEs) with T-VEC were fatigue, chills, and pyrexia. The only grade 3 or 4 AE occurring in ≥ 2% of T-VEC–treated patients was cellulitis (2.1%). No fatal treatment-related AEs occurred. Conclusion: T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial. T-VEC was well tolerated and resulted in a higher DRR (P < .001) and longer median OS (P = .051), particularly in untreated patients or those with stage IIIB, IIIC, or IVM1a disease. T-VEC represents a novel potential therapy for patients with metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Proliferating dendritic cell progenitors in human blood.
Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., & Schuler, G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.83 · Cited by 1,840
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Self-citationMiddleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Self-citationClemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
WHO handbook for reporting results of cancer treatment
Sylvester, R. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90009-4 · Cited by 1,055
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Self-citationTesting for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
Self-citationBedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
Rampling, R., Cruickshank, G., Papanastassiou, V, Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 598
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
Self-citationGlobal perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
Lens, M. B., & Dawes, M. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05708.x · Cited by 567
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Self-citationRepeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Chou, J., & Roizman, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3266 · Cited by 393
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
Self-citationPapanastassiou, V, Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R., & Brown, M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301664 · Cited by 328
Poppers, J., Mulvey, M., Khoo, D., & Mohr, I. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11215-11221.2000 · Cited by 223
Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
Kaufman, H. L., Ruby, C. E., Hughes, T., & Slingluff, C. L. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-11 · Cited by 212
Self-citationEpidemiology of Cutaneous Melanoma in Germany and Worldwide
Garbe, C., & Blum, A. (2001) · Skin Pharmacology and Physiology · doi:10.1159/000056358 · Cited by 209
The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors.
Roizman, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11307 · Cited by 206
Goldsmith, K., Chen, W., Johnson, D. C., & Hendricks, R. L. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.341 · Cited by 206
Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment
Markovic, S. N., Erickson, L. A., Rao, R. D., Weenig, R. H., Pockaj, B. A., Bardia, A., Vachon, C. M., Schild, S. E., McWilliams, R. R., Hand, J. L., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.4.490 · Cited by 165
Herpes simplex virus 1 (HSV-1) for cancer treatment
Shen, Y., & Nemunaitis, J. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700946 · Cited by 159
He, B., Chou, J., Brandimarti, R., Mohr, I., Gluzman, Y., & Roizman, B. (1997) · Journal of Virology · doi:10.1128/jvi.71.8.6049-6054.1997 · Cited by 142
Brown, S. M., MacLean, A. R., McKie, E. A., & Harland, J. (1997) · Journal of Virology · doi:10.1128/jvi.71.12.9442-9449.1997 · Cited by 109
New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma
Byrne, K. T., & Turk, M. J. (2011) · Oncotarget · doi:10.18632/oncotarget.323 · Cited by 105
Puzanov, I. J., Milhem, M. M., Andtbacka, R. H. I., Minor, D. R., Hamid, O., Li, A., Chastain, M. A., Gorski, K. S., Anderson, A., Vanderwalde, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9029 · Cited by 88
Self-citationOncolytic HSV Armed with Platelet Factor 4, an Antiangiogenic Agent, Shows Enhanced Efficacy
Liu, T., Zhang, T., Fukuhara, H., Kuroda, T., Todo, T., Martuza, R. L., Rabkin, S. D., & Kurtz, A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.011 · Cited by 82
ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro
Brown, S. M., MacLean, A. R., Aitken, J. D., & Harland, J. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-12-3679 · Cited by 82
Schultz, E. S., Schuler‐Thurner, B., Stroobant, V., Jenne, L., Berger, T. G., Thielemanns, K., van der Bruggen, P., & Schuler, G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.1304 · Cited by 75
O'Day, S. J., Boasberg, P. D., Piro, L. D., Kristedja, T. S., Wang, H.-J., Martin, M. A., Deck, R., Ames, P., Shinn, K., Kim, H., et al. (2002) · PubMed · Cited by 65
Management of Metastatic Melanoma 2005
O'Day, S. J., & Boasberg, P. D. (2006) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2005.12.002 · Cited by 58
Zeng, G. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00002 · Cited by 55
Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Fukuhara, H., & Todo, T. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780058907 · Cited by 29
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Self-citationOncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Metadata
- Authors
- Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., Middleton, M. R., Miller, W. H., Zager, J. S., Ye, Y., Yao, B., Li, A., Doleman, S., VanderWalde, A., Gansert, J., & Coffin, R. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-09-01
- Volume
- 33
- Issue
- 25
- Pages
- 2780-2788
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2109274792
- Cited by
- 2,634
- References
- 45
- FWCI
- 97.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.